Lisanti Capital Growth’s Viking Therapeutics VKTX Stock Holding History

Lisanti Capital Growth’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,835	Closed	-$1.14M	–	142
2025 Q2	$1.14M	Buy	+42,835	New	+$1.13M	0.31%	92
2025 Q1	–	Sell	-43,950	Closed	-$1.77M	–	159
2024 Q4	$1.77M	Sell	43,950 -2,915	-6%	-$166K	0.43%	85
2024 Q3	$2.97M	Buy	46,865 +6,270	+15%	+$368K	0.75%	59
2024 Q2	$2.15M	Sell	40,595 -13,595	-25%	-$891K	0.52%	74
2024 Q1	$4.44M	Sell	54,190 -294,780	-84%	-$13.1M	1.08%	37
2023 Q4	$6.49M	Buy	+348,970	New	+$4.56M	1.53%	15
2023 Q2	–	Sell	-349,470	Closed	-$5.82M	–	172
2023 Q1	$5.82M	Buy	+349,470	New	+$3.61M	0.81%	51

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Lisanti Capital Growth's VKTX Position: Q3 2025 in Review

Lisanti Capital Growth sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 42,835 shares — an estimated $1.14M sold.

Lisanti Capital Growth first reported a position in VKTX in Q1 2023 and held it in 7 quarters. The position peaked at $6.49M in Q4 2023. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Lisanti Capital Growth reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Lisanti Capital Growth sold 42,835 Viking Therapeutics shares in Q3 2025, an estimated $1.14M.
Lisanti Capital Growth first reported a position in Viking Therapeutics in Q1 2023 and held it in 7 quarters.
Lisanti Capital Growth's Viking Therapeutics position peaked at $6.49M in Q4 2023.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Lisanti Capital Growth's 13F filing for Q3 2025, filed 4 Nov 2025.